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Clinical Characteristics and Risk Factors for Mortality in Patients 
with Meningitis Caused by Staphylococcus aureus and Vancomycin 
Minimal Inhibitory Concentrations Against These Isolates
Wen-Chi Huang, Chen-Hsiang Lee, Jien-Wei Liu*
Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, 
 Chang Gung University College of Medicine, Taiwan.
BACKGROUND/PURPOSE: Bacterial meningitis caused by Staphylococcus aureus is uncommon but has 
a high mortality rate. The aims of this study were to better understand the clinical manifestations of 
S. aureus meningitis, to identify the risk factors for mortality in the affected patients, and to determine the 
levels of vancomycin minimal inhibitory concentrations (MICs) against these pathogens.
METHODS: A retrospective study of patients with S. aureus meningitis hospitalized between December 
2000 and December 2008 was made, and vancomycin MICs against S. aureus isolates was determined 
using Etest.
RESULTS: Among 37 patients with S. aureus meningitis, fever was most commonly observed. Twenty-six 
patients (70.3%) had received prior neurosurgery, and 24 (64.9%) patients were suffering from methicillin-
resistant S. aureus (MRSA) infections. The vancomycin MIC of 2 μg/mL was found in 23 (74.2%) of 31 
S. aureus isolates available for testing. Excluding three patients who did not receive antibiotics for their 
S. aureus meningitis the mortality rate was 35.3% in the 34 remaining patients, with concurrent infective 
endocarditis an independent risk factor for mortality (odds ratio = 21.00; 95% confidence interval, 
1.834–240.515; p = 0.01).
CONCLUSION: Patients with S. aureus meningitis and concurrent infective endocarditis were at a higher 
risk of mortality. A vancomycin MIC of 2 μg/mL against a substantial number of S. aureus isolates that 
grew from the cerebrospinal fluid suggests the importance of obtaining trough vancomycin concentra-
tions of 15–20 μg/mL for the treatment of MRSA meningitis.
KEYWORDS: bacterial meningitis, infective endocarditis, minimal inhibitory concentration, Staphylococcus 
aureus, vancomycin
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Introduction
Bacterial meningitis caused by Staphylococcus aureus is uncom-
mon,1–3 yet results in high mortality in affected patients.3 It 
is also worth noting that patients with methicillin-resistant 
S. aureus (MRSA) bacteremia were reported to have a higher 
mortality rate and longer hospital stays than those with 
methicillin-sensitive S. aureus (MSSA) bacteremia.4 Increasing 
incidence of MRSA meningitis has been observed among all 
S. aureus meningitis cases.1,3 Despite the fact that vancomy-
cin is conventionally the drug of choice for MRSA menin-
gitis, the poor penetration of vancomycin into cerebrospinal 
fluid (CSF) makes treatment of S. aureus meningitis diffi-
cult.5–7 This is especially true when the minimal inhibitory 
concentration (MIC) of vancomycin against a S. aureus 
isolate is approaching the in vitro susceptible breakpoint 
of ≤ 2 μg/mL.8,9 The rarity of S. aureus meningitis limits 
the widespread clinicians’ awareness of this infection entity. 
The aims of this study were to better understand the clini-
cal manifestations of S. aureus meningitis, to identify the 
risk factor(s) for mortality in affected patients, and to 
determine vancomycin MICs against this pathogen.
Methods
Study design, hospital setting and patient population
We carried out a retrospective study of patients admitted 
between December 2000 and December 2008 at Chang 
Gung Memorial Hospital, Kaohsiung (a 2,500 bed facility 
serving as a primary care and tertiary referral center in 
southern Taiwan). The included patients were found in a 
database of the hospital’s clinical microbiology laboratory. 
Diagnoses of meningitis in these patients were based on 
compatible clinical pictures (fever, headache and/or any 
meningeal signs), laboratory data (pleocytosis in CSF), 
and the pure growth of S. aureus in CSF culture with or 
without additional S. aureus isolated from blood culture. 
The medical charts of the included patients were reviewed 
and demographics, clinical and laboratory information 
were collected.
Antimicrobial susceptibility testing
S. aureus isolates were identified by conventional methods 
on a clinical service basis.10 MRSA referred to a S. aureus iso-
late in which the inhibitory zone for cefoxitin was ≤ 19 mm 
by the disk diffusion test; any S. aureus isolate with an in-
hibitory zone greater than 19 mm for cefoxitin was regarded 
as a MSSA.10,11 To obtain the vancomycin MIC, all S. aureus 
isolates were subjected to the Etest in accordance with the 
manufacturer’s instructions (AB Biodisk, Solna, Sweden). 
Briefly, each S. aureus isolate was subcultured on a trypti-
case soy agar plate supplemented with 5% sheep blood, 
which was then incubated overnight (18–24 hours) at 35ºC 
in ambient air. Subcultured S. aureus isolates were inocu-
lated into trypticase soy broth, which was adjusted with 0.9% 
saline to obtain a turbidity comparable to 0.5 McFarland 
Nephelometer standards. The standardized suspension was 
spread onto the surface of a Mueller-Hinton agar plate, which 
was then allowed to dry for 15 minutes before placement 
of a vancomycin Etest strip. The MIC of vancomycin was 
defined as the intercept of the zone of inhibition with the 
graded Etest strip, which was rounded up to the next high-
est two-fold dilution when necessary. S. aureus ATCC29213 
was used as the control strain during susceptibility test-
ing. If the vancomycin MIC was ≤ 2 μg/mL, the tested 
S. aureus isolate was defined as a vancomycin-susceptible 
isolate.12
Definition
Meningitis was defined as nosocomially acquired if it oc-
curred during the patient’s hospitalization or was diagnosed 
upon his or her admission if the patient had been released 
from any healthcare facility less than 1 week before.2,13 
Diabetes mellitus was defined in patients who met at least 
one the following criteria: (1) random plasma glucose level 
greater than 200 mg/dL; (2) fasting plasma glucose level 
greater than 105 mg/dL at recovery from sepsis; and (3) 
being previously diagnosed as a diabetic and taking an oral 
hypoglycemia agent or receiving insulin injections. Chronic 
kidney disease was defined as serum creatinine greater than 
2.0 mg/dL or end-stage renal disease subject to regular he-
modialysis or peritoneal dialysis. Endocarditis was defined 
in patients with concurrent S. aureus bacteremia and one 
or more of the following characteristics: surgical or autopsy 
findings consistent with endocarditis, echocardiographic 
evidence of valvular vegetation, and the presence of embolic 
phenomena.14 Effective empirical antimicrobial therapy re-
ferred to treatment with empirically prescribed antibiotic(s) 
to which the isolated bacteria was susceptible in vitro. 
Suboptimal antimicrobial therapy referred to treatment 
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of MSSA meningitis with vancomycin instead of oxacil-
lin,15,16 or with underdosing of the in vitro susceptible anti-
biotics. The evaluated endpoints were all-cause in-hospital 
mortality.
Statistical analysis
Patients were divided into deceased and surviving groups. By 
univariate analysis, comparison of contingency data between 
the two groups was carried out using a χ2 test or Fisher’s 
exact test, while comparison of continuous data was per-
formed using Student’s t test or Mann-Whitney U test. A 
p value < 0.1 in univariate analyses was entered into a multiple 
logistic regression model to identify independent risk fac-
tors for in-hospital mortality of patients with S. aureus 
meningitis. Variables with a two-tailed p value < 0.05 were 
considered statistically significant. All analyses were per-
formed using the SPSS version 15.0 (SPSS Inc., Chicago, 
IL, USA).
Results
Clinical characteristics
Thirty-seven cases (6.5%) of S. aureus meningitis were iden-
tified among 573 cases of bacterial meningitis in Chang 
Gung Memorial Hospital during the study period. The male/
female ratio was 3.625 (29/8), and median age was 43.4 years 
(range, 0–86 years). The demographic and clinical infor-
mation for these patients is summarized in Table 1. We 
found a variety of underlying diseases/conditions among 
these patients; these included chronic kidney disease (16.2%), 
malignancies (24.3%), diabetes mellitus (5.4%), concurrent 
infective endocarditis (18.9%) and intravenous drug use 
(13.5%). Of the S. aureus meningitis cases, 29 (78.4%) were 
nosocomially acquired and 26 cases (70.3 %) had received 
prior neurosurgery. Fever, the most commonly encountered 
presentation, was found in 27 (73%) patients. Among the 
28 patients whose blood culture was available, S. aureus bac-
teremia was found in only 10 cases (35.7%).
Of the subgroup of seven patients with infective endo-
carditis, six were male. Fever (5/7) and consciousness change 
(6/7) were the most frequent clinical presentations and 
most of the infections were community acquired (6/7). 
The mortality rate in patients with concurrent infective 
endocarditis (6/7 fatal) was higher than those without. 
Among these seven patients, five were intravenous drug 
users, one had end-stage renal disease and another had 
chronic osteomyelitis. MRSA isolates were found in four 
cases, except the three intravenous drug user cases, and 
for three of these MRSA isolates, the vancomycin MICs 
(2 μg/mL) were high.
Microbiological characteristics
The 37 S. aureus isolates were universally susceptible to van-
comycin, and 24 (64.9%) of them were resistant to methi-
cillin. Compared with the 31 S. aureus isolates that survived 
preservation, a vancomycin MIC of 2 μg/mL was found in 
23 (74.2%) isolates, 1 μg/mL in 7 (22.6%), and 0.5 μg/mL 
in 1 (3.2%). The annual distribution of the MIC for vanco-
mycin of 2 μg/mL against the S. aureus isolates in the years 
between 2002 and 2008 is shown in the Figure.
Table 1. Demographic characteristics and clinical outcomes 
of 37 patients with Staphylococcus aureus meningitis
Variable n (%)a
Age (yr) 43.4 (0–86)
Sex, male 29 (78.4)
Clinical manifestations
 Fever 27 (73.0)
 Altered consciousness 18 (48.6)
 Seizure 2 (5.4)
 CSF leakage 7 (18.9)
 Shock 5 (13.5)
 Concurrent bacteremia 10 (35.7)b
 Infective endocarditis 7 (18.9)
Underlying diseases/conditions
 Chronic kidney disease 6 (16.2)
 Malignancies 9 (24.3)
 Diabetes mellitus 2 (5.4)
 Intravenous drug use 5 (13.5)
 Post-neurosurgery 26 (70.3)
 Nosocomial-acquisition 29 (78.4)
MRSA meningitis 24 (64.9)
In-hospital mortalityc 14 (37.8)
aData presented as median (range) or n (%), one patient may have 
more than one clinical manifestation and underlying disease/condi-
tion; bblood culture data only available for 28 patients; cincludes three 
patients that did not receive antibiotics aimed at meningitis, and who 
were not eligible for assessment of risk factor for in hospital-mortality 
(see text for details). CSF = cerebrospinal fluid; MRSA = methicillin-
resistant Staphylococcus aureus.
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Treatment and prognosis
Three of the 37 patients included in the study did not re-
ceive antibiotics aimed at S. aureus meningitis during hos-
pitalization because of either poor clinical status (head 
trauma and in a vegetative status) or delayed diagnosis. 
These three patients were excluded from assessment of 
risk factors for in-hospital mortality. Among the 34 assess-
able patients, 18 (52.9%) received effective empirical treat-
ment, while 24 (70.6%) received suboptimal antimicrobial 
treatment. Twelve patients died, giving an overall mortal-
ity rate of 35.3%. Univariate analyses disclosed that when 
compared with the surviving group, patients in the de-
ceased group had significantly higher proportions of sep-
tic shock (33.3% vs. 0%; p = 0.01), chronic kidney disease 
(41.7% vs. 4.5%; p = 0.01), intravenous drug use (33.3% vs. 
4.5%; p = 0.04), and concurrent infective endocarditis 
(50.0% vs. 4.5%; p < 0.01) (Table 2). A significantly lower 
proportion of patients that were post-neurosurgery were 
found in the deceased group (41.7% vs. 81.8%; p = 0.03) when 
compared with the surviving group (Table 2). Logistic regres-
sion indicated that only concurrent infective endocarditis 
(odds ratio = 21.00; 95% confidence interval, 1.834–240.515; 
p = 0.01) was an independent risk factor for in-hospital 
mortality in patients with S. aureus meningitis.
Discussion
The incidence of S. aureus meningitis in our study was sim-
ilar to a previously published series of 19 patients admitted 
to our hospital between 1986 and 2000.1 We found similari-
ties in age, sex, post-neurosurgery, proportions of MRSA 
meningitis, nosocomial acquisition rate and mortality rate, 
but lower proportions of fever, altered consciousness and 
seizure at diagnosis of S. aureus meningitis (Table 3). These 
data suggested an earlier diagnosis of S. aureus meningitis 
before full development of symptoms and signs of infection 
of the central nervous system in patients in our series. 
However, the previous data1 and our current data indicate 
no improvement in patients with S. aureus meningitis in 
our hospital over the past 22 years in terms of survival.
Nearly 70% of our patients developed S. aureus meningitis 
after neurosurgery, which was comparable to figures in other 
studies ranging from 43% to 80%.3,17–20 The 37.8% (14/37 
patients) in-hospital mortality of our patients was compa-
rable to those previously reported, which ranged between 
14–77%.2–3,17–22 The variability in mortality might result 
from the differences in clinical severity and underlying 
diseases/conditions between patients in different series.
The mortality rate in patients with hematogenous 
S. aureus meningitis was reported to be higher than that in 
patients with post-operative S. aureus meningitis (19–71% vs. 
11–28%).17–23 Of note, the in-hospital mortality rate in pa-
tients with S. aureus meningitis and concurrent infective 
endocarditis in this series was found to be as high as 85.7% 
(6/7 patients). One recent report revealed that the mortality 
rate significantly increased in patients with endocarditis 
who became infected with S. aureus once neurological signs 
clinically developed.24 Our data, together with those from 
previous reports25 indicated the existence of endocarditis 
in approximately 15% of S. aureus bacteremic patients, un-
derscoring the importance of a diligent search for possible 
endocarditis in S. aureus bacteremic patients because the 
likelihood of fatality in patients with S. aureus meningitis 
is high if there is a coexisting endocarditis.
Of the six patients with chronic kidney disease in this 
series, four of the five deceased patients were infected with 
a MRSA (Table 2). Adjusting for renal function to avoid 
toxicity, vancomycin at a dose of 1 g per 24 hours or 1 g per 
72 hours was prescribed in our cases, resulting in a trough 
serum vancomycin concentration below 15 μg/mL, leading 
to treatment failure,26 as a trough serum vancomycin con-
centration of 15–20 μg/mL is recommended for treatment 
of MRSA meningitis.27 In patients with normal renal func-
tion (creatinine clearance 70–100 mL/min) and S. aureus 
with low vancomycin MIC (< 1 μg/mL), conventional dos-
ing (loading with 25–30 mg/kg followed by 15–20 mg/kg 
q8–12 h) renders a sufficient target therapeutic level (area 
under concentration curve/MIC > 400) in patients with infec-
tions including meningitis. However, there is no consensus 
Figure. Annual distribution of vancomycin minimum inhibitory 
concentrations from 2002 to 2008.
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on vancomycin dosing for patients with chronic kidney 
disease.27 In this scenario, one might either determine the 
optimal vancomycin dosing by adjusting the prescribed 
antibiotic based on the measurement of its serum trough 
level or use alternative antibiotics such as linezolid for 
patients with MRSA meningitis.
The penetration of vancomycin into the CSF varies 
greatly, and CSF:serum vancomycin ratios were reported to 
range from 0–0.18 in hosts with non-inflamed meninges to 
0.36–0.48 in those with an inflamed meninges.26 Despite 
availability of high serum vancomycin levels, unsatisfactory 
CSF vancomycin levels leading to clinical and bacterio-
logical ineffectiveness have been previously reported.28 
Another study showed that intravenous administration of 
vancomycin barely reached satisfactory levels (5 μg/mL).29 
Given this non-favorable antibiotic penetration level in 
CSF, successful treatment with intrathecal/intraventricular 
vancomycin administration with or without additional 
intravenous administration of vancomycin for patients 
with shunt- or infusion pump-related meningitis were 
previously reported.29–32 A variety of recommended van-
comycin intrathecal/intraventricular doses was found in 
the literature. The potential meningeal irritation due to 
high vancomycin concentration in CSF prevents unlimited 
intrathecal/intraventricular use of vancomycin.33 Intra-
ventricular vancomycin at 10 mg per day was reported to 
be safe and therapeutically efficacious in meningitis pa-
tients.31,33 However, in cases other than ventriculoperito-
neal shunt or extraventricular drainage-related meningitis, 
the therapeutic effects of intrathecal/intraventricular 
vancomycin use for meningitis caused by MRSA have not 
been extensively studied.
Table 2. Comparisons of demographic and clinical data between the deceased and surviving groups of patients with Staphylococcus 
aureus meningitisa
Variable
 Deceased group  Survived group  p
 (n = 12) (n = 22)
Age, mean (yr) 40.4 43.6 0.74
Sex, male 9 (75.0) 17 (77.3) 1.00
Clinical manifestation
 Fever 7 (58.3) 17 (77.3) 0.27
 Altered consciousness 7 (58.3) 9 (40.9) 0.48
 Seizure 0 (0) 2 (9.1) 0.53
 Shock 4 (33.3) 0 (0) 0.01
 CSF leakage 0 (0) 5 (22.7) 0.14
 Concurrent bacteremia, A/B (%)b 7/12 (58.3) 3/15 (20.0) 0.06
 Infective endocarditis 6 (50.0) 1 (4.5) < 0.01
Underlying disease/condition
 Diabetes mellitus 2 (16.7) 0 (0) 0.12
 Chronic kidney disease 5 (41.7) 1 (4.5) 0.01
 Malignancy 2 (16.7) 6 (27.3) 0.68
 Intravenous drug abuser 4 (33.3) 1 (4.5) 0.04
 Post-neurosurgery 5 (41.7) 18 (81.8) 0.03
 Nosocomial-acquisition 7 (58.3) 19 (86.4) 0.10
MRSA meningitis 7 (58.3) 14 (63.6) 1.00
Vancomycin MIC of 2 μg/mL, A/B (%)b 9/11 (81.8) 12/18 (66.7) 0.67
Effective empirical treatment 7 (58.3) 11 (50.0) 0.73
Suboptimal treatment 7 (58.3) 17 (77.3) 0.27
aData presented as mean or n (%). One patient might have more than one clinical manifestation and underlying disease/condition; bA/B = number 
of patients/number of patients with data available. CSF = cerebrospinal fluid; MIC = minimum inhibitory concentration; MRSA = methicillin-
resistant Staphylococcus aureus.
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The higher the vancomycin MIC against MRSA, the 
more likely the vancomycin treatment is to fail in MRSA 
bacteremia.8,9,34,35 Specifically, the estimated rates for 
treatment success in patients with MRSA bacteremia 
was 56% if the vancomycin MIC was ≤ 0.5 μg/mL, and 
as low as 10% if the vancomycin MIC was ≥ 1 μg/mL.8,34 
The widespread escalation of MICs in S. aureus isolates36 
implicates the decreasing success rate in the vancomycin 
treatment of MRSA bacteremia. Theoretically, an in-
crease in the failure rate for vancomycin treatment of 
MRSA meningitis can be anticipated. The vancomycin-
susceptible breakpoint in the guidelines set out by the 
Clinical and Laboratory Standards Institute has been 
altered from 4 μg/mL down to 2 μg/mL.27,37 Current 
Infectious Diseases Society of America guidelines rec-
ommend clinicians consider alternative therapies when 
the vancomycin MIC is ≥ 2 μg/mL and the MRSA men-
ingitis patient has normal renal function, as the target 
area under concentration curve/MIC is unachievable 
following conventional vancomycin dosing.27 The high 
mortality rate in our patients may be due to the high 
percentage (74.2%) of vancomycin MICs being 2 μg/mL.
Some limitations in this study have to be addressed. 
First, the sample size was small. Second, being a retrospec-
tive study, the clinical severity of each case was unable 
to be assessed. Third, the vancomycin concentrations in 
serum and CSF in the affected patients were not mea-
sured. Nevertheless, this study shows that concurrent 
infective endocarditis was a risk factor for mortality in 
patients with S. aureus meningitis, along with a vanco-
mycin MIC of 2 μg/mL against a substantial number of 
S. aureus isolates from the CSF of affected patients in 
southern Taiwan. This suggests that the achievement 
of serum vancomycin concentrations ranging 15–20 μg/
mL is extremely important when treating patients with 
MRSA meningitis.
Table 3. Comparison of demographic and clinical data between the previous study (1986–2000) and this series (2000–2008) of 
adults with Staphylococcus aureus meningitisa
Variable
 Previous studyb Current study p
 (n = 19) (n = 30)
Age (yr)a 51 56 0.98
Sex, male 12 (63.2) 25 (83.3) 0.17
Clinical manifestations
 Fever 18 (100) 22 (73.3) 0.02
 Altered consciousness  16 (94.1) 18 (60.0) 0.02
 Seizure  5 (31.3) 1 (3.3) 0.02
 Shock 2 (12.5) 5 (16.7) 1.00
Underlying diseases/conditions
 Diabetes mellitus 10 (52.6) 2 (6.7) < 0.001
 Chronic kidney disease 1 (5.3) 6 (20.0) 0.22
 Malignancy 2 (10.5) 8 (26.7) 0.28
 Infectious endocarditis 1 (5.3) 5 (16.7) 0.38
 Intravenous drug abuser 2 (10.5) 7 (23.3) 0.45
 Nosocomial-acquisition 13 (68.4) 22 (73.3) 0.75
 Post-neurosurgery 11 (57.9) 19 (63.3) 0.77
MRSA meningitis 11 (57.9) 20 (66.7) 0.56
In-hospital mortality 6 (31.6) 11 (36.7) 0.77
aData presented as median or n (%); badapted from Chang WN et al [1]. MRSA = methicillin-resistant Staphylococcus aureus.
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